1. Home
  2. CRVS vs EQV Comparison

CRVS vs EQV Comparison

Compare CRVS & EQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRVS
  • EQV
  • Stock Information
  • Founded
  • CRVS 2014
  • EQV 2024
  • Country
  • CRVS United States
  • EQV United States
  • Employees
  • CRVS N/A
  • EQV N/A
  • Industry
  • CRVS Biotechnology: Pharmaceutical Preparations
  • EQV
  • Sector
  • CRVS Health Care
  • EQV
  • Exchange
  • CRVS Nasdaq
  • EQV Nasdaq
  • Market Cap
  • CRVS 451.0M
  • EQV 442.6M
  • IPO Year
  • CRVS 2016
  • EQV 2024
  • Fundamental
  • Price
  • CRVS $8.94
  • EQV $9.93
  • Analyst Decision
  • CRVS Buy
  • EQV
  • Analyst Count
  • CRVS 4
  • EQV 0
  • Target Price
  • CRVS $12.83
  • EQV N/A
  • AVG Volume (30 Days)
  • CRVS 1.0M
  • EQV 101.6K
  • Earning Date
  • CRVS 11-12-2024
  • EQV 01-01-0001
  • Dividend Yield
  • CRVS N/A
  • EQV N/A
  • EPS Growth
  • CRVS N/A
  • EQV N/A
  • EPS
  • CRVS N/A
  • EQV N/A
  • Revenue
  • CRVS N/A
  • EQV N/A
  • Revenue This Year
  • CRVS N/A
  • EQV N/A
  • Revenue Next Year
  • CRVS N/A
  • EQV N/A
  • P/E Ratio
  • CRVS N/A
  • EQV N/A
  • Revenue Growth
  • CRVS N/A
  • EQV N/A
  • 52 Week Low
  • CRVS $1.30
  • EQV $9.88
  • 52 Week High
  • CRVS $10.00
  • EQV $9.95
  • Technical
  • Relative Strength Index (RSI)
  • CRVS 60.34
  • EQV N/A
  • Support Level
  • CRVS $8.02
  • EQV N/A
  • Resistance Level
  • CRVS $8.71
  • EQV N/A
  • Average True Range (ATR)
  • CRVS 0.86
  • EQV 0.00
  • MACD
  • CRVS -0.17
  • EQV 0.00
  • Stochastic Oscillator
  • CRVS 52.25
  • EQV 0.00

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

About EQV EQV Ventures Acquisition Corp.

EQV Ventures Acquisition Corp is a blank check company.

Share on Social Networks: